Factors Influencing Outcomes and Survival in Anal Cancer.


Journal

Current oncology (Toronto, Ont.)
ISSN: 1718-7729
Titre abrégé: Curr Oncol
Pays: Switzerland
ID NLM: 9502503

Informations de publication

Date de publication:
02 Sep 2024
Historique:
received: 21 07 2024
revised: 27 08 2024
accepted: 30 08 2024
medline: 27 9 2024
pubmed: 27 9 2024
entrez: 27 9 2024
Statut: epublish

Résumé

We aim to ascertain prognostic factors in the current management of anal cancer within this study. We reviewed the management and outcomes of anal cancer cases over a seven-year period, inclusive (2016-2023). The primary objectives were to assess the demographic characteristics, clinical presentation, and outcomes of all anal cancer patients within our institution. Kaplan-Meier survival analysis was used to estimate survival differences between cohorts, with statistical significance determined using log-rank testing. Cox proportional hazards regression was utilised to identify prognostic factors. Cox regression hazard ratios were reported along with confidence intervals and The median follow-up time for the study was 29.8 months. Seventy-five patients with anal cancer were included in this study, with 88% (66/75) being squamous cell carcinoma (SCC) and the majority having regional disease (82.7% (62/75)). The median age at diagnosis was 63.4 years (36-94). There was a female preponderance (57.3% (43/75)). In total, 84% (63/75) underwent definitive chemoradiation ( Presenting characteristics including stage, nodal, and differentiation status remain key prognostic indicators in those diagnosed with anal malignancy.

Sections du résumé

BACKGROUND BACKGROUND
We aim to ascertain prognostic factors in the current management of anal cancer within this study.
METHODS METHODS
We reviewed the management and outcomes of anal cancer cases over a seven-year period, inclusive (2016-2023). The primary objectives were to assess the demographic characteristics, clinical presentation, and outcomes of all anal cancer patients within our institution. Kaplan-Meier survival analysis was used to estimate survival differences between cohorts, with statistical significance determined using log-rank testing. Cox proportional hazards regression was utilised to identify prognostic factors. Cox regression hazard ratios were reported along with confidence intervals and
RESULTS RESULTS
The median follow-up time for the study was 29.8 months. Seventy-five patients with anal cancer were included in this study, with 88% (66/75) being squamous cell carcinoma (SCC) and the majority having regional disease (82.7% (62/75)). The median age at diagnosis was 63.4 years (36-94). There was a female preponderance (57.3% (43/75)). In total, 84% (63/75) underwent definitive chemoradiation (
CONCLUSION CONCLUSIONS
Presenting characteristics including stage, nodal, and differentiation status remain key prognostic indicators in those diagnosed with anal malignancy.

Identifiants

pubmed: 39330009
pii: curroncol31090381
doi: 10.3390/curroncol31090381
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

5151-5163

Auteurs

Hugo C Temperley (HC)

Department of Radiology, St. James's Hospital, D08 NHY1 Dublin, Ireland.
Department of Surgery, St. James's Hospital, D08 NHY1 Dublin, Ireland.
Trinity St. James's Cancer Institute, D08 NHY1 Dublin, Ireland.

Benjamin M Mac Curtain (BM)

Department of Surgery, St. James's Hospital, D08 NHY1 Dublin, Ireland.

Niall J O'Sullivan (NJ)

Department of Radiology, St. James's Hospital, D08 NHY1 Dublin, Ireland.
Department of Surgery, St. James's Hospital, D08 NHY1 Dublin, Ireland.

Cormac Mulhall (C)

Department of Surgery, St. James's Hospital, D08 NHY1 Dublin, Ireland.

Tatiana S Temperley (TS)

Department of Surgery, St. James's Hospital, D08 NHY1 Dublin, Ireland.

Brian J Mehigan (BJ)

Department of Surgery, St. James's Hospital, D08 NHY1 Dublin, Ireland.

John O Larkin (JO)

Department of Surgery, St. James's Hospital, D08 NHY1 Dublin, Ireland.

Paul H McCormick (PH)

Department of Surgery, St. James's Hospital, D08 NHY1 Dublin, Ireland.

Colm Kerr (C)

Department of Infectious Diseases, St. James's Hospital, D08 NHY1 Dublin, Ireland.

David Gallagher (D)

Department of Medical Oncology, St. James's Hospital, D08 NHY1 Dublin, Ireland.
Department of Genetics, St. James's Hospital, D08 NHY1 Dublin, Ireland.

Colm Bergin (C)

Department of Infectious Diseases, St. James's Hospital, D08 NHY1 Dublin, Ireland.

Charles Gillham (C)

Department of Radiation Oncology, St. James's Hospital, D08 NHY1 Dublin, Ireland.

Michael E Kelly (ME)

Department of Surgery, St. James's Hospital, D08 NHY1 Dublin, Ireland.
Trinity St. James's Cancer Institute, D08 NHY1 Dublin, Ireland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH